Abstract
Bayer are developing copanlisib (Aliqopa (TM))-a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor-as a treatment for various haematological and ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
